The US FDA has posted details, including company and FDA Briefing Materials, for the Tuesday, July 19, 2016 Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) meeting. The Committee will discuss biologics license application (BLA) 761032, for brodalumab injection, a human monoclonal antibody, submitted by Valeant Pharmaceuticals Luxembourg S.à.r.l (Valeant), proposed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
See the SAC Tracker report